FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

Accord Healthcare Tadalafil Tablets Recall

Tadalafil Tablets, USP, 2

Accord Healthcare, Inc. · Durham, NC

Risk level
Class II
Reported by FDA
Mar 8, 2023
Recall ID
D-0414-2023
Check your lot numberHow we source this data

Summary

Accord Healthcare recalled Tadalafil Tablets starting Feb 7, 2023. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0414-2023 on Mar 8, 2023. Reason: CGMP Deviations: recalling drug products following an FDA inspection. Status: Terminated.

Why it was recalled

CGMP Deviations: recalling drug products following an FDA inspection.

Product description

Tadalafil Tablets, USP, 2.5 mg Rx Only, Packaged as: a) 30-count bottle NDC 16729-369-10, UPC 3 16729 36910 7; b) 500-count bottle NDC 16729-369-16, UPC 3 16729 36916 9; Manufactured for: Accord Healthcare, Inc., Durham, NC 27703. Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213 INDIA

Lot numbers, UPCs & expiration codes

Batches: a) P2002522, Exp. Date 4/30/2023; P2005817, P2005816, Exp. Date 10/31/2023; P2203687, Exp. Date 6/30/2025; b) P2002521, Exp. Date 4/30/2023; P2005818, Exp. Date 10/31/2023; P2100075, Exp. Date 12/31/2023; P2100996, P2100997, P2100998, P2100999, Exp. Date 1/31/2024;

Where it was sold

United States including Puerto Rico and Canada

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0414-2023
Classification
Class II
Status
Terminated
Recall initiated
Feb 7, 2023
FDA report date
Mar 8, 2023
Quantity
36,773 bottles
Recall type
Voluntary: Firm initiated
Recalling firm
Accord Healthcare, Inc.

Original FDA data

Every field from FDA enforcement report D-0414-2023, exactly as published.

Show all FDA fields
City
Durham
State
NC
Status
Terminated
Country
United States
Event ID
91657
Address
1009 Slater Rd Ste 210B
Code information
Batches: a) P2002522, Exp. Date 4/30/2023; P2005817, P2005816, Exp. Date 10/31/2023; P2203687, Exp. Date 6/30/2025; b) P2002521, Exp. Date 4/30/2023; P2005818, Exp. Date 10/31/2023; P2100075, Exp. Date 12/31/2023; P2100996, P2100997, P2100998, P2100999, Exp. Date 1/31/2024;
Postal code
27703-8446
Report date
Mar 8, 2023
Product type
Drugs
Recall number
D-0414-2023
Classification
Class II
Recalling firm
Accord Healthcare, Inc.
Product quantity
36,773 bottles
Termination date
Apr 22, 2024
Reason for recall
CGMP Deviations: recalling drug products following an FDA inspection.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Tadalafil Tablets, USP, 2.5 mg Rx Only, Packaged as: a) 30-count bottle NDC 16729-369-10, UPC 3 16729 36910 7; b) 500-count bottle NDC 16729-369-16, UPC 3 16729 36916 9; Manufactured for: Accord Healthcare, Inc., Durham, NC 27703. Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213 INDIA
Distribution pattern
United States including Puerto Rico and Canada
Recall initiation date
Feb 7, 2023
Initial firm notification
Letter
Center classification date
Mar 2, 2023

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0414-2023, published Mar 8, 2023. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls